Related references
Note: Only part of the references are listed.Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
Susan B. Kesmodel et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
Nadia Herbeck et al.
BREAST CARE (2013)
German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
Michael Gnant et al.
CANCER TREATMENT REVIEWS (2012)
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
Robert Coleman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H. G. Paterson et al.
LANCET ONCOLOGY (2012)
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
C. L. Shapiro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
H. Eidtmann et al.
ANNALS OF ONCOLOGY (2010)
Bone turnover across the menopause transition The role of gonadal inhibins
Kristy M. Nicks et al.
SKELETAL BIOLOGY AND MEDICINE (2010)
Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
P. A. Newcomb et al.
BRITISH JOURNAL OF CANCER (2010)
Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women
Rowan T. Chlebowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
Gad Rennert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft et al.
LANCET ONCOLOGY (2010)
Tumor Self-Seeding by Circulating Cancer Cells
Mi-Young Kim et al.
CELL (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
Bent Kristensen et al.
ACTA ONCOLOGICA (2008)
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
M. C. Winter et al.
CANCER TREATMENT REVIEWS (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant et al.
LANCET ONCOLOGY (2008)
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid
Janet E. Brown et al.
CLINICAL CANCER RESEARCH (2007)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
T Powles et al.
BREAST CANCER RESEARCH (2006)
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
I Fogelman et al.
OSTEOPOROSIS INTERNATIONAL (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
